By Sneha S K and Sahil Pandey
April 15 (Reuters) – Cosmo Pharmaceuticals said on Wednesday its experimental hair loss treatment showed sustained hair growth and long-term safety in men with common pattern baldness after a year of use.
The year‑long extension study follows late-stage data reported in December, when the topical drug, called clascoterone, met its main goals in two large studies where it showed significant hair growth in 1,465 men over six months.
(Reporting by Sneha S K and Sahil Pandey in Bengaluru; Editing by Maju Samuel)
Comments